Conclusions
obesity, T2D, metabolic disorder, prediabetes, hypoglycemia
ADVERSE REACTIONS, OBESITY, METABOLIC DISORDER, PREDIABETES, INSULIN TOLERANCE, HYPOGLYCEMIA, INSULIN RESISTANCE, PRE-DIABETES
CLM as a novel microbial ingredient elicited substantially positive anti-diabetic effects during the intake period (12 weeks), involving especially ameliorated glycemic control of FBG, peripheral insulin action, and reduced C-peptide and HbA1c, via improving insulin resistance. CLM is also considered a safe ingredient with no adverse reactions after 12 weeks of use. To the best of our knowledge, this is a well-defined human randomized controlled trial to examine the anti-diabetic effect of novel microbial mycelium on hypoglycemia and insulin resistance. The results of this study proposed that the microbial medium of CLM might reduce blood sugar, especially FBG and insulin tolerance, and its effect could be helpful for patients with impaired FBG or pre-diabetes. The efficacy of CLM against T2D could be beneficial as a functional supplementation considering that the size of the population with metabolic disorder (T2D, prediabetes, obesity) has been increasing, while anti-diabetic treatment is limited.